^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KSD-101

    i
    Other names: KSD-101, Autologous monocyte-derived DCs pulsed with allogeneic EBV-transformed B-lymphoblastoid cell line lysate
    Associations

    News

    Trials
    Company:
    Hengsai Bio
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    23d
    KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=0, Withdrawn, Kousai Bio Co., Ltd. | Active, not recruiting --> Withdrawn
    Trial withdrawal
    |
    KSD-101
    7ms
    KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Sun Yat-sen University
    New P1 trial
    |
    KSD-101
    8ms
    KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=12, Recruiting, Kousai Bio Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KSD-101
    8ms
    KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Kousai Bio Co., Ltd. | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    KSD-101
    1year
    Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study (ASH 2023)
    Our current study shows that KSD-101 has excellent safety and good preliminary efficacy against EBV-associated Hematologic Neoplasms with efficient induction of immune responses. The results indicate that KSD-101 is a promising therapeutic reagent for the treatment of EBV-associated Hematologic Neoplasms. Larger prospective studies and longer follow-up time is needed to be conducted.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    KSD-101
    1year
    KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Kousai Bio Co., Ltd.
    New P1 trial
    |
    KSD-101
    over1year
    KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=9, Enrolling by invitation, Tongji Hospital | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    KSD-101
    over1year
    KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Shanghai Changhai Hospital
    New P1 trial
    |
    KSD-101